30 Day Trial

BARE BONES content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Reimbursement / Regulatory

BONESUPPORT Receives FDA Approval to Initiate IDE Clinical Study -

BONESUPPORT received FDA approval to launch an Investigational Device Exemption study of CERAMENT G in the treament of open diaphyseal tibial fractures, slated to start by the end of 2016.

The randomized, multicenter, controlled, 230-patient FORTIFY trial will evaluate safety and efficacy of the injectable gentamicin antibiotic-eluting bone graft substitute as part of surgical repair. BONESUPPORT intends for at least 50% of the study data to come from U.S. subjects. 

At the start of 2016, BONESUPPORT announced the milestone of >20,000 patients treated worldwide with CERAMENT products. CERAMENT G received CE Mark approval and launched in the EU in 1Q13, while CERAMENT V (vancomycin-eluting) entered EU launch in early 2Q15


This article is a Member-only item of content. Members, please log in to read the complete post.
If you are not yet a Member, click here to learn more about purchasing ORTHOWORLD Membership.